microRNA -378a-3p Restrains the Proliferation of Retinoblastoma Cells but Promotes Apoptosis of Retinoblastoma Cells via Inhibition of FOXG1.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
11 05 2020
Historique:
entrez: 20 5 2020
pubmed: 20 5 2020
medline: 29 9 2020
Statut: ppublish

Résumé

More recently, literature has emerged providing findings about the novelty of microRNAs (miR)-targeted therapeutics in the treatment of retinoblastoma (RB). The prime objective of this study was to identify the potential role of miR-378a-3p and its regulation in RB cells via forkhead box G1 (FOXG1). The expression of miR-378a-3p and FOXG1 in the clinical RB tissues was determined using RNA quantitation and Western blot assays. The interaction between miR-378a-3p and FOXG1 was identified using dual luciferase reporter gene assay. The potential effects of miR-378a-3p on the RB cell biological processes were evaluated by conducting gain- and loss-of-function studies of miR-378a-3p and FOXG1, followed by cell viability, cell cycle progression, and apoptosis measurements. Furthermore, experiments were performed in nude mice to assess its effects on tumor formation. miR-378a-3p was poorly expressed, whereas FOXG1 was highly expressed in RB tissues and cells. miR-378a-3p bound to the FOXG1 3' untranslated region and negatively modulated its expression. The overexpression of miR-378a-3p was found to decrease RB cell viability and to promote cell apoptosis in vitro, whereas overexpressed FOXG1 reversed the regulatory effects of miR-378a-3p on RB cellular behaviors. In nude mice, the restoration of miR-378a-3p by miR-378a-3p agomir was shown to play a role in the reduction of tumor volume and size relative to nude mice injected with negative control-agomir. Our findings identified that increased miR-378a-3p exerted an inhibitory effect on RB cell proliferation by targeting FOXG1, suggesting the role of miR-378a-3p as a novel therapeutic target for RB.

Identifiants

pubmed: 32428232
pii: 2766215
doi: 10.1167/iovs.61.5.31
pmc: PMC7405766
doi:

Substances chimiques

FOXG1 protein, human 0
Forkhead Transcription Factors 0
Foxg1 protein, mouse 0
MIRN378 microRNA, human 0
MicroRNAs 0
Nerve Tissue Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

31

Références

Biomed Pharmacother. 2018 Sep;105:805-812
pubmed: 29913409
Cell Signal. 2016 Aug;28(8):850-60
pubmed: 27094723
Nat Rev Dis Primers. 2015 Aug 27;1:15021
pubmed: 27189421
Genes Dev. 2011 Aug 15;25(16):1663-7
pubmed: 21852531
Clin Invest Med. 2010 Aug 01;33(4):E223-33
pubmed: 20691140
J Neurosci. 2008 Oct 8;28(41):10415-21
pubmed: 18842901
FEBS J. 2014 Mar;281(5):1355-65
pubmed: 24289859
Clin Transl Gastroenterol. 2016 Mar 10;7:e152
pubmed: 26963002
Biochem Biophys Res Commun. 2018 Sep 26;504(1):46-53
pubmed: 30172378
Thorac Cancer. 2018 Aug;9(8):939-949
pubmed: 29897167
BMC Cancer. 2018 Dec 10;18(1):1230
pubmed: 30526546
J Control Release. 2019 Mar 28;298:177-185
pubmed: 30776396
Acta Pharmacol Sin. 2013 Jul;34(7):870-9
pubmed: 23624759
Annu Rev Pathol. 2015;10:547-62
pubmed: 25621664
Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109799
pubmed: 31349439
Genes Dev. 2017 Apr 15;31(8):757-773
pubmed: 28465359
Plant Biol (Stuttg). 2013 Jul;15(4):686-93
pubmed: 23590453
Sci Rep. 2015 Aug 10;5:13170
pubmed: 26255816
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13910-5
pubmed: 26508630
Ophthalmology. 2018 Nov;125(11):1812
pubmed: 30318041
Int J Mol Med. 2018 Jul;42(1):381-391
pubmed: 29693138
Clin Cancer Res. 2017 Jul 1;23(13):e98-e106
pubmed: 28674118
Hum Pathol. 2015 Dec;46(12):1859-71
pubmed: 26433703
Mini Rev Med Chem. 2016;16(6):430-54
pubmed: 26202204
Mol Med Rep. 2019 Aug;20(2):1333-1342
pubmed: 31173241
Oncol Res. 2018 May 7;26(4):581-591
pubmed: 28550678
Biomed Pharmacother. 2019 Oct;118:109111
pubmed: 31336343
Biomed Pharmacother. 2018 Nov;107:1410-1417
pubmed: 30257357
FEBS Lett. 2014 Jun 5;588(12):2107-14
pubmed: 24815696
Curr Med Chem. 2013;20(29):3574-81
pubmed: 23834181
Nat Commun. 2013;4:2956
pubmed: 24356439
Trends Mol Med. 2016 Oct;22(10):863-876
pubmed: 27567287
J Cancer. 2018 Feb 11;9(5):778-783
pubmed: 29581755
Nat Commun. 2018 Jan 31;9(1):461
pubmed: 29386624
Tumour Biol. 2016 Aug;37(8):11177-86
pubmed: 26935060
Mol Oncol. 2018 Jun;12(6):775-787
pubmed: 29316219
Semin Cancer Biol. 2016 Oct;40-41:35-47
pubmed: 27038646

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH